Select Language
Complement C3
Complement C3 Overview
| English Name | Complement C3 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 13 | Target Synonym | Complement C3，Complement Component C3a，Epididymis Secretory Sperm Binding Protein Li 62p，C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1，C3bc，C3adesArg，C3，Complement Component C3b，Complement Component 3，C3a Anaphylatoxin，Prepro-C3，CPAMD1，Acylation-Stimulating Protein Cleavage Product，HEL-S-62p，AHUS5，ARMD9，ASP，C3a，C3b |
| Highest Development Stage | Approved | ||
| English Name | Complement C3 |
| Target Synonym | Complement C3，Complement Component C3a，Epididymis Secretory Sperm Binding Protein Li 62p，C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1，C3bc，C3adesArg，C3，Complement Component C3b，Complement Component 3，C3a Anaphylatoxin，Prepro-C3，CPAMD1，Acylation-Stimulating Protein Cleavage Product，HEL-S-62p，AHUS5，ARMD9，ASP，C3a，C3b |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 13 |
| Highest Development Stage | Approved |
Complement C3 Product List
- Product Category
Protein (5)Kits (1)
- Product Status
Launched (6)
- Species
Human (4)Mouse (1)Cynomolgus (1)
- Tag
His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)- (1)
- Conjugate
Unconjugated (4)Biotin-labeled (1)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CO3-H52H3 |  Human | HEK293 | Human Complement C3 Protein, His Tag, low endotoxin (MALS verified) |  |  |  |
HOT CO3-H82E8 | Human | HEK293 | Biotinylated Human Complement C3 Protein, His,Avitag™ (MALS verified) |  | | |
HOT CO3-M52H4 |  Mouse | HEK293 | Mouse Complement C3 Protein, His Tag (MALS verified) |  | | |
CEA-B263 | Human | - | Human Complement C3 ELISA Kit | |||
CO3-H5253 | Human | HEK293 | Human Complement component 3 Protein, Fc Tag (MALS verified) |  | | |
CO3-C52H5 |  Cynomolgus | HEK293 | Cynomolgus Complement C3 Protein, His Tag (MALS verified) |  | | |
Total: 6
- 1
Complement C3 Background
C3 is the major complement component serum. It is mainly synthesized by macrophages and liver. C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. It is cleaved into two fragments, C3a and C3b. C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
Complement C3 Synonyms
Complement C3,CPAMD1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Efdamrofusp alfa | IBI-302 | Phase 3 Clinical | AP Biosciences Inc | Diabetic macular oedema; Macular Degeneration; Plaque psoriasis; Wet Macular Degeneration | Details |
| NGM-621 | NGM-621 | Phase 2 Clinical | NGM Biopharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Geographic Atrophy | Details |
| RG-002-C-0106 | RG-002-C-0106; RG002C0106 | Phase 2 Clinical | Beijing Xuanjingrui Pharmaceutical Technology Co Ltd, Suzhou Xuanjing Biotechnology Co Ltd | Complement-Mediated Diseases; Glomerulonephritis, IGA; Hemolysis; Nephrotic Syndrome | Details |
| APL-3007 | APL-3007 | Phase 2 Clinical | Apellis Pharmaceuticals Inc | Geographic Atrophy | Details |
| SGB-9768 | SGB-9768 | Phase 2 Clinical | Suzhou Sanegene Bio Inc | C3 glomerulopathy; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Kidney Diseases | Details |
| KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | Details |
| ALXN-2030 | ALXN-2030 | Phase 2 Clinical | Alexion Pharmaceuticals Inc | Rejection of renal transplantation; Rejection of organ transplantation | Details |
| LP-005 | LP-005; RX-001 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies | Details |
| ARO-C3 | ARO-C3; ARO-C-3 | Phase 2 Clinical | Arrowhead Pharmaceuticals Inc | C3 glomerulopathy; Glomerulonephritis, IGA | Details |
| CG-001 | CG-001 | Phase 1 Clinical | Chengdu Konjin Co Ltd | Autoimmune Diseases; Hemoglobinuria, Paroxysmal; Myasthenia Gravis | Details |
| BI-C | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Geographic Atrophy; Retinal Diseases | Details | |
| Ebribafusp alfa | ADX-097 | Phase 1 Clinical | Q32 Bio Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Nephrosis, Lipoid | Details |
| NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pegcetacoplan | APL-2 | Approved | Apellis Pharmaceuticals Inc | Aspaveli, Empaveli, Syfovre | United States | Hemoglobinuria, Paroxysmal | Apellis Pharmaceuticals Inc | 2021-05-14 | Amyotrophic Lateral Sclerosis; Anemia, Hemolytic, Autoimmune; C3 glomerulopathy; Delayed Graft Function; Geographic Atrophy; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Hemoglobinuria, Paroxysmal; Kidney Failure, Chronic; Lupus Nephritis; Macular Degeneration; Motor Neuron Disease; Rejection of renal transplantation | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main